Enzalutamide, modalités pratiques d’utilisation d’une nouvelle hormonothérapie

Ferlay, 2013, Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur J Cancer, 49, 1374, 10.1016/j.ejca.2012.12.027 Taplin, 2004, Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence, J Cell Biochem, 91, 483, 10.1002/jcb.10653 Yuan, 2009, Mechanisms mediating androgen receptor reactivation after castration, Urol Oncol, 27, 36, 10.1016/j.urolonc.2008.03.021 Scher, 2005, Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis, J Clin Oncol, 23, 8253, 10.1200/JCO.2005.03.4777 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 Molina, 2011, Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling, J Urol, 185, 787, 10.1016/j.juro.2010.10.042 Chen, 2004, Molecular determinants of resistance to antiandrogen therapy, Nat Med, 10, 33, 10.1038/nm972 Tran, 2009, Development of a second-generation antiandrogen for treatment of advanced prostate cancer, Science, 324, 787, 10.1126/science.1168175 Scher, 2010, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study, Lancet, 375, 1437, 10.1016/S0140-6736(10)60172-9 Scher, 2012, Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 Miller K, Scher H, Fizazi K, et al. Enzalutamide improves health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: results from the phase 3 AFFIRM trial. J Clin Oncol 31, 2013 (suppl 6; abstr 17). Scher HI, Fizazi K, Saad F, et al. Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. J Clin Oncol 31, 2013 (suppl 6; abstr 6). Loriot Y, Fizazi K, De Bono JS, Forer D, Hirmand M, Scher HI. Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. J Clin Oncol 31, 2013 (suppl; abstr 5065). Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013 ; 368 : 138-48. Loriot, 2013, Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100), Ann Oncol, 24, 1807, 10.1093/annonc/mdt136 Hu, 2012, Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer, Cancer Res, 72, 3457, 10.1158/0008-5472.CAN-11-3892 Efstathiou E, Titus MA, Tsavachidou D, et al. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: a preliminary report. J Clin Oncol 29 : 2011 (suppl ; abstr 4501). Carver, 2011, Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer, Cancer Cell, 19, 575, 10.1016/j.ccr.2011.04.008 Baum, 2002, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet, 359, 2131, 10.1016/S0140-6736(02)09088-8 Smith MR, Borre M, Rathenborg P, et al. Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC). J Clin Oncol 31, 2013 (suppl; abstr 5001). Agence nationale de sécurité du médicament et des produits de santé (ANSM). Fiche d’ATU. Protocole d’utilisation thérapeutique du crizotinib–ATU cohorte, 2012. Disponible sur le site internet : http://ansm.sante.fr/Activites/Autorisations-Temporaires-d-Utilisation-ATU/ATU-de-cohorte/Liste-des-specialites-faisant-actuellement-l-objet-d-une-ATU-de-cohorte/ENZALUTAMIDE-ASTELLAS-40-mg-capsule-molle/(language)/fre-FR